Yahoo Finance • last year
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (... Full story
Yahoo Finance • last year
Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing FREMONT, Calif., June 26, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced th... Full story
Yahoo Finance • last year
FREMONT, Calif., June 13, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporatio... Full story
Yahoo Finance • 2 years ago
Participants Aaron L. Tachibana; CFO & COO; Personalis, Inc. Caroline V. Corner; MD; Westwicke Partners, LLC Christopher M. Hall; President, CEO & Director; Personalis, Inc. Richard Chen; Executive VP of R&D and Chief Medical Officer;... Full story
Yahoo Finance • 2 years ago
FREMONT, Calif., April 19, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 202... Full story
Yahoo Finance • 2 years ago
Participants Aaron L. Tachibana; Interim CEO & CFO; Personalis, Inc. Chris Hall Richard Chen; Senior VP of R&D and Chief Medical Officer; Personalis, Inc. Unidentified Analyst Vivien Bias Caroline V. Corner; MD; Westwicke Partners, L... Full story
Yahoo Finance • 2 years ago
FREMONT, Calif., January 04, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31,... Full story
Yahoo Finance • 2 years ago
MENLO PARK, Calif., July 12, 2022--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to J... Full story
Yahoo Finance • 2 years ago
It's nice to see the Personalis, Inc. (NASDAQ:PSNL) share price up 20% in a week. But that is meagre solace when you consider how the price has plummeted over the last year. During that time the share price has plummeted like a stone, down... Full story
Yahoo Finance • 3 years ago
MENLO PARK, Calif., April 20, 2022--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In con... Full story
Yahoo Finance • 3 years ago
In this article, we discuss 10 stocks under $10 in Cathie Wood’s portfolio. If you want to see some more stocks in this selection, go see Cathie Wood's Portfolio: 5 Stocks Under $10. Cathie Wood is the chief executive officer and chief in... Full story
Yahoo Finance • 3 years ago
MENLO PARK, Calif., March 31, 2022--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference... Full story